Press Releases

Month Year

Month Year

Apr 1, 2019

Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference

--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--

Read more
Apr 1, 2019

Insmed to Present at the H.C. Wainwright Global Life Sciences Conference

Read more
Mar 27, 2019

Insmed Announces Management Changes

Read more
Mar 4, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Feb 22, 2019

Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018--

Read more
Feb 20, 2019

Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference

Read more
Feb 15, 2019

Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019

Read more
Feb 4, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jan 7, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jan 4, 2019

Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

-ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the Fourth Quarter of 2018-

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation